| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Bladder cancer has a high recurrence rate and low survival rate, and patient's quality of life are significantly reduced due to side effects of treatment and surgical treatment. In response, we aimed to develop novel therapeutic and preventive methods focusing on QOL using naftopidil, an α1 blocker-type oral dysuria treatment, by taking advantage of the idea of drug repositioning (DR). We were able to prepare a formulation that can expect antitumor effect from two directions by naftopidil in blood and its urinary metabolite. It is a promising achievement of establishing a novel therapeutic method for bladder cancer with safety- established naftopidil, its application for prevention of recurrence, and development of novel anticancer drugs.
|
